Volume 6, Issue 9

Reasons to Switch/Not Switch ART Regimens

In this issue:

Why should people living with HIV consider switching from a currently successful ART regimen? Are they looking for better tolerability, with fewer or less bothersome side effects? Do they need a regimen with fewer drug-drug interactions? Do they want a regimen to decrease pill burden and/or dosing frequency that will improve their ability to take it (adherence)? And if they’re considering change, which ART options are likely the most beneficial? What does the evidence say?  

Those are some of the questions Dr. Natasha Chida, from the Division of Infectious Diseases at the Johns Hopkins University School of Medicine, discusses in her analysis of the current literature in this issue of eHIV Review. 

Learning objectives:

  • Describe clinical situations in which certain single-tablet regimens may be utilized as switch regimens in persons who are virally suppressed. 
  • Summarize patient characteristics that preclude the use of certain single-tablet regimens as switch regimens in persons who are virally suppressed. 


Natasha Chida, MD, MSPH
Natasha Chida, MD, MSPH

Assistant Professor of Medicine, Division of Infectious Diseases  
Johns Hopkins University School of Medicine 
Baltimore, Maryland

Program Directors:

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, Maryland

Matthew Spinelli, MD, MAS

Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California

Justin Alves, RN, ACRN, CARN

Nurse Educator – Office Based Addiction Treatment, Training and Technical Assistance Program
Boston Medical Center
Boston, Massachusetts

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: June 24, 2021
Expiration date: June 23, 2023